Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
59K characters. Original on sec.gov ·
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| MD&A | Overview |
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at September 30, 2023 and June 30, 2023, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three months ended September 30, 2023 and 2022. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2023 Form 10-K.
| 2 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
Overview of Consolidated Results
Revenue
Revenue for the three months ended September 30, 2023 increased 10 percent to $54.8 billion due to branded and specialty pharmaceutical sales growth, largely from existing customers.
GAAP and Non-GAAP Operating Earnings/(Loss)
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| GAAP operating earnings/(loss) | $ | (14) | $ | 137 | N.M. | ||||||||||||
| Shareholder cooperation agreement costs | — | 6 | |||||||||||||||
| Restructuring and employee severance | 25 | 29 | |||||||||||||||
| Amortization and other acquisition-related costs | 64 | 71 | |||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 537 | 153 | |||||||||||||||
| Litigation (recoveries)/charges, net | (41) | 27 | |||||||||||||||
| Non-GAAP operating earnings | $ | 571 | $ | 423 | 35 | % |
The sum of the components and certain computations may reflect rounding adjustments.
We had a GAAP operating loss of $14 million during the three months ended September 30, 2023 and GAAP operating earnings of $137 million during the three months ended September 30, 2022, which included the impact of pre-tax goodwill impairment charges related to the Medical Segment of $581 million and $154 million, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional information related to goodwill impairment. During the three months ended September 30, 2023, the GAAP operating loss reflected favorable impacts from Pharmaceutical and Medical segment profit, a $53 million gain on the divestiture of the Outcomes™ business and net litigation recoveries.
Non-GAAP operating earnings increased 35 percent to $571 million during the three months ended September 30, 2023, primarily due to an increase in Pharmaceutical and Medical segment profit as described in the "Results of Operations" section of this MD&A.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 3 |
| MD&A | Overview |
GAAP and Non-GAAP Diluted EPS
| Three Months Ended September 30, | |||||||||||||||||
| ($ per share) | 2023 (2) | 2022 (2) | Change | ||||||||||||||
| GAAP diluted EPS (1) | $ | 0.02 | $ | 0.40 | N.M. | ||||||||||||
| Shareholder cooperation agreement costs | — | 0.01 | |||||||||||||||
| Restructuring and employee severance | 0.07 | 0.08 | |||||||||||||||
| Amortization and other acquisition-related costs | 0.19 | 0.20 | |||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net (3) | 1.57 | 0.44 | |||||||||||||||
| Litigation (recoveries)/charges, net | (0.12) | 0.07 | |||||||||||||||
| Non-GAAP diluted EPS (1) | $ | 1.73 | $ | 1.20 | 44 | % |
The sum of the components and certain computations may reflect rounding adjustments.
(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
(3) Impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $581 million related to the Medical segment recorded during the three months ended September 30, 2023. For fiscal 2024, the estimated net tax benefit related to this impairment charge is $45 million and is included in the annual effective tax rate. As a result, the amount of tax benefit for three months ended September 30, 2023 increased approximately by an incremental $99 million and is expected to increase the provision for income taxes during the remainder of the fiscal year.
During the three months ended September 30, 2022, impairments and (gain)/loss on disposal of assets, net included a pre-tax impairment charge of $154 million related to the Medical segment. For fiscal 2023, the estimated net tax benefit related to the impairment was $12 million and was included in the annual effective tax rate. As a result, the amount of tax benefit for the three months ended September 30, 2022 increased approximately by an incremental $22 million and increased the provision for income taxes during the remainder of fiscal 2023.
During the three months ended September 30, 2023, GAAP diluted EPS decreased due to the factors impacting GAAP operating earnings/(loss) discussed above. The goodwill impairment charges related to the Medical segment had $(1.74) and $(0.44) per share after-tax impacts on GAAP diluted EPS during the three months ended September 30, 2023 and 2022, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 and Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional detail.
During the three months ended September 30, 2023, non-GAAP diluted EPS increased 44 percent to $1.73 due to the factors impacting non-GAAP operating earnings discussed above and a lower share count as a result of share repurchases, partially offset by unfavorable changes in discrete tax items.
Cash and Equivalents
Our cash and equivalents balance was $3.9 billion at September 30, 2023 compared to $4.0 billion at June 30, 2023. During the three months ended September 30, 2023, net cash provided by operating activities was $545 million, which includes the impact of our annual payment of $378 million related to the April 2022 agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "National Opioid Settlement Agreement"). In addition, we deployed cash of $500 million for share repurchases and $92 million for capital expenditures.
| 4 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Overview |
Significant Developments in Fiscal 2024 and Trends
Pharmaceutical Segment
COVID-19 Vaccine Distribution
Pharmaceutical segment profit was favorably impacted during the three months ended September 30, 2023 on a year-over-year basis in part due to the company beginning to distribute the recently commercially available COVID-19 vaccines following U.S. Food and Drug Administration approval of updated vaccines in September 2023. We expect seasonal benefits from COVID-19 vaccine distribution to continue into the second quarter of fiscal 2024. The ultimate timing, magnitude and profit impact of vaccine distribution volume remains uncertain during fiscal 2024 and beyond.
Generics Program
The performance of our Pharmaceutical segment generics program positively impacted the year-over-year comparison of Pharmaceutical segment profit during the three months ended September 30, 2023. The Pharmaceutical segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes, the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health") and generic pharmaceutical contract manufacturing and sourcing costs.
The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, generic pharmaceutical manufacturer pricing changes and generic pharmaceutical contract manufacturing and sourcing costs all impact Pharmaceutical segment profit and are subject to risks and uncertainties. These risks and uncertainties may impact Pharmaceutical segment profit and consolidated operating earnings during the remainder of fiscal 2024.
Medical Segment
Inflationary Impacts
Beginning in fiscal 2022, Medical segment profit was negatively affected by inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities, labor and global supply chain constraints. Since that time, we have taken actions to partially mitigate these impacts, including implementing certain price increases and evolving our pricing and commercial contracting processes to provide us with greater pricing flexibility. In addition, decreases in some product-related costs have been recognized as the higher-cost inventory moved through our supply chain and was replaced by lower cost inventory. These net inflationary impacts negatively affected Medical segment profit during fiscal 2023, however, the net inflationary impacts were less significant during the three months ended September 30, 2023 and had a favorable impact on Medical segment profit on a year-over-year basis.
We expect these net inflationary impacts to continue to affect Medical segment profit during the remainder of fiscal 2024, but to a significantly lesser extent than in fiscal 2023 and prior periods, due to our mitigation actions, together with continued decreases in certain product-related costs. However, these inflationary costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. Our actions to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent or on the timeline we anticipate.
Volumes within Products and Distribution
Medical segment profit was adversely impacted during fiscal 2023 in part due to lower volumes within products and distribution, which includes our Cardinal Health branded medical products. We expect Cardinal Health branded medical products sales growth in fiscal 2024 and beyond. The timing, magnitude and profit impact of this anticipated sales growth is subject to risks and uncertainties, which may impact Medical segment profit.
Medical Unit Goodwill
Due to an increase in the risk-free interest rate, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”) during the three months ended September 30, 2023. This testing resulted in a pre-tax charge of $581 million which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail. Adverse changes in key assumptions or a significant change in industry or economic trends during the remainder of fiscal 2024 and beyond could result in additional goodwill impairment.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 5 |
| MD&A | Overview |
Shareholder Cooperation Agreement
In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P.(together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations. In May 2023, we extended the term of the Cooperation Agreement until the later of July 15, 2024 or until Elliott's representative ceases to serve on, or resigns from, the Board. In connection with this extension, the Board extended the term of the Business Review Committee until July 15, 2024.
The evaluation and implementation of any actions recommended by the Business Review Committee and the Board have impacted and may continue to impact our business, financial position and results of operations during the remainder of fiscal 2024 and beyond. We have incurred, and may incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee.
| 6 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Results of Operations |
Results of Operations
Revenue


| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| Pharmaceutical | $ | 51,006 | $ | 45,828 | 11 | % | |||||||||||
| Medical | 3,760 | 3,778 | — | % | |||||||||||||
| Total segment revenue | 54,766 | 49,606 | 10 | % | |||||||||||||
| Corporate | (3) | (3) | N.M. | ||||||||||||||
| Total revenue | $ | 54,763 | $ | 49,603 | 10 | % |
Pharmaceutical Segment
Pharmaceutical segment revenue increased during the three months ended September 30, 2023 due to branded and specialty pharmaceutical sales growth, which increased revenue by $5.2 billion, largely from existing customers.
Medical Segment
Medical segment revenue was relatively flat during the three months ended September 30, 2023. The adverse impact of personal protective equipment ("PPE") volumes and pricing was mostly offset by sales growth in at-Home Solutions and the effect of price increases to partially mitigate inflationary impacts. PPE volumes and pricing includes the impact from the prior year exit of our non-healthcare gloves portfolio in connection with our simplification strategy.
Cost of Products Sold
Cost of products sold increased 10 percent to $53.0 billion due to the factors affecting the changes in revenue and gross margin.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 7 |
| MD&A | Results of Operations |
Gross Margin


| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| Gross margin | $ | 1,768 | $ | 1,614 | 10 | % |
Gross margin increased during the three months ended September 30, 2023 primarily due to the beneficial comparison to the prior-year net inflationary impacts in the Medical segment, increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from COVID-19 vaccine distribution, and the performance of our generics program in the Pharmaceutical segment.
Gross margin rate was relatively flat during the three months ended September 30, 2023 with the impact of unfavorable changes in overall product mix mostly offset by the performance of our generics program in the Pharmaceutical segment and the beneficial comparison to the prior-year net inflationary impacts in the Medical segment. The changes in overall product mix were primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate.
Distribution, Selling, General, and Administrative ("SG&A") Expenses
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| SG&A expenses | $ | 1,197 | $ | 1,197 | — | % |
During the three months ended September 30, 2023, SG&A expenses were flat with higher costs to support sales growth offset by the beneficial impact of enterprise-wide cost-savings measures.
| 8 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Results of Operations |
Segment Profit
We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| Pharmaceutical | $ | 507 | $ | 431 | 18 | % | |||||||||||
| Medical | 71 | (8) | N.M. | ||||||||||||||
| Total segment profit | 578 | 423 | 37 | % | |||||||||||||
| Corporate | (592) | (286) | N.M. | ||||||||||||||
| Total consolidated operating earnings/(loss) | $ | (14) | $ | 137 | N.M. |
Pharmaceutical Segment Profit
Pharmaceutical segment profit increased during the three months ended September 30, 2023, primarily due to increased contribution from branded pharmaceutical and specialty pharmaceutical products, which includes the favorable impact from COVID-19 vaccine distribution, and the performance of our generics program.
Medical Segment Profit
Medical segment profit increased during the three months ended September 30, 2023 due to the beneficial comparison to the prior-year net inflationary impacts, including the effects of mitigation actions.
Corporate
The changes in Corporate during the three months ended September 30, 2023 are due to the factors discussed in the "Other Components of Consolidated Operating Earnings/(Loss)" section that follows.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 9 |
| MD&A | Results of Operations |
Other Components of Consolidated Operating Earnings/(Loss)
In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:
| Three Months Ended September 30, | |||||||||||
| (in millions) | 2023 | 2022 | |||||||||
| Restructuring and employee severance | $ | 25 | $ | 29 | |||||||
| Amortization and other acquisition-related costs | 64 | 71 | |||||||||
| Impairments and (gain)/loss on disposal of assets, net | 537 | 153 | |||||||||
| Litigation (recoveries)/charges, net | (41) | 27 |
Restructuring and Employee Severance
During the three months ended September 30, 2023, restructuring and employee severance costs were primarily related to certain projects resulting from reviews of our strategy, portfolio, capital-allocation framework and operations and the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2022, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $64 million and $71 million for the three months ended September 30, 2023 and 2022, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
During the three months ended September 30, 2023 and 2022, we recognized $581 million and $154 million pre-tax non-cash goodwill impairment charges, respectively, related to the Medical segment, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements."
During the three months ended September 30, 2023, we recognized a pre-tax gain of $53 million related to the divestiture of the Outcomes™ business. See Note 2 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Litigation (Recoveries)/Charges, Net
During the three months ended September 30, 2023, we recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff of $41 million.
During the three months ended September 30, 2022, we recognized $21 million of estimated losses and legal defense costs associated with the inferior vena cava ("IVC") filter product liability claims. See Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Earnings Before Income Taxes
In addition to the items discussed above, earnings before income taxes was impacted by the following:
| Three Months Ended September 30, | |||||||||||||||||
| (in millions) | 2023 | 2022 | Change | ||||||||||||||
| Other (income)/expense, net | $ | (2) | $ | 2 | N.M. | ||||||||||||
| Interest expense, net | 14 | 25 | (44) | % | |||||||||||||
Interest Expense, Net
During the three months ended September 30, 2023, interest expense, net, decreased by 44 percent primarily due to increased interest income from cash and equivalents.
| 10 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Results of Operations |
Provision for/(Benefit from) Income Taxes
During the three months ended September 30, 2023 and 2022, the effective tax rate was 122.5 percent and (0.7) percent, respectively. The increase in the effective tax rate for the three months ended September 30, 2023 compared to the prior-year period was primarily due to the tax effect of the goodwill impairment charge as well as certain other discrete items. See Note 7 of the “Notes to Condensed Consolidated Financial Statements” for additional information.
Tax Effects of Goodwill Impairment Charge
During the three months ended September 30, 2023, we recognized a $581 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $45 million for fiscal 2024.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for the three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $99 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2023. This interim tax benefit will reverse in future quarters of fiscal 2024.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 11 |
| MD&A | Liquidity and Capital Resources |
Liquidity and Capital Resources
We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs as described below. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.
Cash and Equivalents
Our cash and equivalents balance was $3.9 billion at September 30, 2023 compared to $4.0 billion at June 30, 2023. During the three months ended September 30, 2023, net cash provided by operating activities was $545 million, which includes the impact of our annual payment of $378 million related to the National Opioid Settlement Agreement. In addition, we deployed cash of $500 million for share repurchases and $92 million for capital expenditures.
At September 30, 2023, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at September 30, 2023 included $558 million of cash held by subsidiaries outside of the United States.
Other Financing Arrangements and Financial Instruments
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2023 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC was added as a seller under our committed receivables sales facility. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2023, we were in compliance with this financial covenant.
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both September 30, 2023 and June 30, 2023.
| 12 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| MD&A | Liquidity and Capital Resources |
Capital Deployment
Opioid Litigation Settlements
We had $5.45 billion accrued at September 30, 2023 related to certain opioid litigation settlements, as further described within Note 6 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to occur through 2038. During the three months ended September 30, 2023, we made our third annual payment of $378 million under the National Opioid Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made.
Capital Expenditures
Capital expenditures during the three months ended September 30, 2023 and 2022 were $92 million and $70 million, respectively.
Dividends
On each of May 11, 2023 and August 9, 2023, our Board of Directors approved a quarterly dividend of $0.5006 per share, or $2.00 per share on an annualized basis, which were paid on July 15, 2023 and October 15, 2023 to shareholders of record on July 3, 2023 and October 3, 2023, respectively.
Share Repurchases
During the three months ended September 30, 2023, we deployed $500 million for repurchases of our common shares under an accelerated share repurchase ("ASR") program. We funded the repurchases with available cash. An ASR program initiated in the first quarter of fiscal 2024 concluded in the second quarter of fiscal 2024, which reduced the amount remaining under our existing share repurchase authorization to approximately $3.7 billion. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 13 |
| MD&A | Other Items |
Other Items
The MD&A in our 2023 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2023. There have been no subsequent material changes outside the ordinary course of business to those items.
Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June 30, 2023. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2023 Form 10-K.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2023 Form 10-K and our other filings with the SEC since June 30, 2023.
Goodwill
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.
Medical Unit Goodwill
Due to an increase in the risk-free interest rate during the three months ended September 30, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. Our determination of the
estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the three months ended September 30, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent. The carrying value of the Medical Unit at September 30, 2023 after recognizing the impairment charge was $5.3 billion, of which $141 million was goodwill. See Note 4 of the "Notes to Condensed Consolidated Financial Statements" for further discussion.
While we consider the assumptions used in our determination of the estimated fair value of the Medical Unit to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2024 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; manufacturing cost
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 14 |
| MD&A | Other Items |
inefficiencies resulting from lower than anticipated sales volume, an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends.
Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent to 11.5 percent or decrease the terminal growth rate by a hypothetical 1.75 percent to 0.25 percent, the fair value for the Medical Unit would have further decreased by approximately $200 million. Additionally, a hypothetical 25 basis point decrease in long-term gross margin rates, which could be impacted by changes in Cardinal Health branded medical product sales growth rate assumptions, would have further decreased the fair value for the Medical Unit by approximately $200 million.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 15 |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
-
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
-
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
-
Shareholder cooperation agreement costs includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance.
-
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance and realigning operations.
-
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial
| 16 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
-
Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
-
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
-
Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt divided by (earnings before income taxes adjusted for the eight items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 17 |
| Explanation and Reconciliation of Non-GAAP Financial Measures |
GAAP to Non-GAAP Reconciliations
| Operating Earnings/ (Loss) | Operating Earnings Growth Rate | Earnings/ (Loss) Before Income Taxes | Provision for/(Benefit from) Income Taxes | Net Earnings****1 | Net Earnings****1 Growth Rate | Diluted EPS****1 | Diluted EPS****1 Growth Rate | |||||||||||||||||||||||||||||||
| (in millions, except per common share amounts) | Three Months Ended September 30, 2023 | |||||||||||||||||||||||||||||||||||||
| GAAP | $ | (14) | N.M. | $ | (26) | $ | (32) | $ | 5 | N.M. | $ | 0.02 | N.M. | |||||||||||||||||||||||||
| Restructuring and employee severance | 25 | 25 | 7 | 18 | 0.07 | |||||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 64 | 64 | 17 | 47 | 0.19 | |||||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net2 | 537 | 537 | 146 | 391 | 1.57 | |||||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | (41) | (41) | (12) | (29) | (0.12) | |||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 571 | 35 | % | $ | 560 | $ | 126 | $ | 433 | 32 | % | $ | 1.73 | 44 | % | ||||||||||||||||||||||
| Three Months Ended September 30, 2022 | ||||||||||||||||||||||||||||||||||||||
| GAAP | $ | 137 | (67) | % | $ | 110 | $ | (1) | $ | 110 | (59) | % | $ | 0.40 | (57) | % | ||||||||||||||||||||||
| Shareholder cooperation agreement costs | 6 | 6 | 2 | 4 | 0.01 | |||||||||||||||||||||||||||||||||
| Restructuring and employee severance | 29 | 29 | 7 | 22 | 0.08 | |||||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 71 | 71 | 18 | 53 | 0.20 | |||||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net2 | 153 | 153 | 34 | 119 | 0.44 | |||||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | 27 | 27 | 7 | 20 | 0.07 | |||||||||||||||||||||||||||||||||
| Non-GAAP | $ | 423 | (20) | % | $ | 396 | $ | 67 | $ | 328 | (12) | % | $ | 1.20 | (7) | % |
1 Attributable to Cardinal Health, Inc.
2 For the three months ended September 30, 2023 and 2022, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $581 million and $154 million, respectively, related to the Medical segment. For fiscal 2024 and 2023, the net tax benefits related to these impairment charges were $45 million and $12 million, respectively, and were included in the annual effective tax rate. As a result, the tax benefits for the three months ended September 30, 2023 and 2022 increased approximately by an incremental $99 million and $22 million, respectively, and will increase the provision for income taxes during the remainder of fiscal 2024 and 2023, respectively.
The sum of the components and certain computations may reflect rounding adjustments.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.
| 18 | Cardinal Health | Q1 Fiscal 2024 Form 10-Q |
| Other |
Previous: Cover and table of contents · Next: Item 3. Quantitative and Qualitative Disclosures about Market Risk